ArticleAnnals of translational medicine2019

Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?

Willemijn S M E Theelen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.